315 related articles for article (PubMed ID: 30991648)
1. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ubc9-Induced CRMP2 SUMOylation Disrupts Glioblastoma Cell Proliferation.
Wang L; Ji S
J Mol Neurosci; 2019 Nov; 69(3):391-398. PubMed ID: 31267313
[TBL] [Abstract][Full Text] [Related]
3. Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.
Bernstock JD; Ye D; Gessler FA; Lee YJ; Peruzzotti-Jametti L; Baumgarten P; Johnson KR; Maric D; Yang W; Kögel D; Pluchino S; Hallenbeck JM
Sci Rep; 2017 Aug; 7(1):7425. PubMed ID: 28785061
[TBL] [Abstract][Full Text] [Related]
4. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic targets and agents for glioblastoma therapy--part II.
Lo HW
Anticancer Agents Med Chem; 2010 Sep; 10(7):511. PubMed ID: 21070189
[No Abstract] [Full Text] [Related]
6. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
7. SnapShot: glioblastoma multiforme.
Kotliarova S; Fine HA
Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
[No Abstract] [Full Text] [Related]
8. Emerging therapeutic targets and agents for glioblastoma therapy - part I.
Lo HW
Anticancer Agents Med Chem; 2010 Jul; 10(6):437. PubMed ID: 20937018
[No Abstract] [Full Text] [Related]
9. Targeting SUMOylation cascade for diabetes management.
Sireesh D; Bhakkiyalakshmi E; Ramkumar KM; Rathinakumar S; Jennifer PS; Rajaguru P; Paulmurugan R
Curr Drug Targets; 2014; 15(12):1094-106. PubMed ID: 25230117
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
11. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
[TBL] [Abstract][Full Text] [Related]
12. Analysis Suggests Drug Combos for Glioblastoma.
Cancer Discov; 2016 Jun; 6(6):OF2. PubMed ID: 27165727
[TBL] [Abstract][Full Text] [Related]
13. An Experimenter's Guide to Glioblastoma Invasion Pathways.
de Gooijer MC; Guillén Navarro M; Bernards R; Wurdinger T; van Tellingen O
Trends Mol Med; 2018 Sep; 24(9):763-780. PubMed ID: 30072121
[TBL] [Abstract][Full Text] [Related]
14. Targeting the SUMO pathway for neuroprotection in brain ischaemia.
Yang W; Sheng H; Wang H
Stroke Vasc Neurol; 2016 Sep; 1(3):101-107. PubMed ID: 28959470
[TBL] [Abstract][Full Text] [Related]
15. The post-translational modification, SUMOylation, and cancer (Review).
Han ZJ; Feng YH; Gu BH; Li YM; Chen H
Int J Oncol; 2018 Apr; 52(4):1081-1094. PubMed ID: 29484374
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
Mecca C; Giambanco I; Donato R; Arcuri C
Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
[TBL] [Abstract][Full Text] [Related]
17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
19. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
Bastien JI; McNeill KA; Fine HA
Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
